Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.65 |
| ▸ | CPA1 | P15085 | 3/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.63 |
| ▸ | CPA2 | P48052 | 2/20 | 0.63 |
| ▸ | CPA4 | Q9UI42 | 2/20 | 0.63 |
| ▸ | CPB1 | P15086 | 1/20 | 0.63 |
| ▸ | GNPAT | O15228 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.62 |
| ▸ | MMP7 | P09237 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.62 |
| ▸ | MMP12 | P39900 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
| ▸ | ACE | P12821 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15692334 | 1.00 | MME (0.65) | MMECPA1ACE2CPA2CPA4 | |
| SCHEMBL15692325 | 0.94 | MME (0.69) | MMECPA1ACE2CPA2CPA4 | |
| SCHEMBL31326264 | 0.94 | MME (0.69) | MMECPA1ACE2CPA2CPA4 | |
| SCHEMBL8532925 | 0.93 | MME (0.61) | MMECPA1ACE2CPA2CPA4 | |
| SCHEMBL7421185 | 0.93 | CPA1 (0.59) | MMECPA1ACE2CPA2CPA4 | |
| SCHEMBL17948648 | 0.93 | CPA1 (0.63) | MMECPA1ACE2CPA2CPA4 | |
| SCHEMBL31609331 | 0.92 | MME (0.56) | MMECPA1ACE2CPA2CPA4 | |
| SCHEMBL8537049 | 0.91 | CAPN1 (0.61) | MMECPA1ACE2CPA2CPA4 | |
| SCHEMBL15692372 | 0.90 | MME (0.67) | MMECPA1ACE2MMP2MMP7 | |
| SCHEMBL15649671 | 0.90 | MME (0.67) | MMECPA1ACE2MMP2MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294581-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN IN PROTEASE INHIBITORS AND ANALOGS THEREOF | UNIV YALE (US) | 2024-09-05 | — | — | US | disclosed |
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | YALE UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | LPXN, LAP3, PEPD | MME 186/4885CPA1 99/4885ACE2 428/4885 |
| US-20240294581-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN IN PROTEASE INHIBITORS AND ANALOGS THEREOF | LPXN, LAP3, PEPD | MME 154/4885CPA1 92/4885ACE2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.